Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1995 Mar 4;310(6979):575-9.
doi: 10.1136/bmj.310.6979.575.

Drug treatment of Parkinson's disease

Affiliations
Review

Drug treatment of Parkinson's disease

N Quinn. BMJ. .

Abstract

A wide variety of drugs is available for treating Parkinson's disease, including anticholinergics, amantadine levodopa, dopamine agonists, and selegiline. In younger patients (less than 50) levodopa is usually delayed provided that adequate relief of symptoms can be achieved with other drugs. In older patients (greater than 70) levodopa should be started as soon as symptom relief is required. Between these ages there is no consensus, but at present most such patients should probably be given controlled release levodopa before a dopamine agonist is added. Fluctuations can often be alleviated by giving controlled release preparations of levodopa, by giving small doses at frequent intervals, by adding selegiline or a long acting oral agonist, or by subcutaneous apomorphine. Dyskinesia can be peak dose, diphasic, or "off period." The diphasic form is hardest to alleviate. Psychiatric side effects should initially be managed by changing the antiparkinsonian treatment before resorting to antipsychotic drugs.

PubMed Disclaimer

Comment in

References

    1. Psychol Med. 1987 Nov;17(4):899-904 - PubMed
    1. Ann Neurol. 1988 Jan;23(1):73-8 - PubMed
    1. Lancet. 1976 Feb 7;1(7954):292-6 - PubMed
    1. Arch Neurol. 1978 May;35(5):261-3 - PubMed
    1. N Engl J Med. 1984 Feb 23;310(8):483-8 - PubMed

MeSH terms